SynthesisBMC cardiovascular disorders2026
Left Atrial Appendage Aneurysm (LAAA): an updated descriptive systematic review of 25 contemporary cases (2023-2025).
Synthesis in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft atrial appendage aneurysm (LAAA) is a rare cardiac anomaly with fewer than 200 cases reported until 2022 and no established diagnostic or management guidelines. This updated systematic review synthesizes all cases published between January 2023 and July 2025, highlighting clinical patterns, imaging findings, and evolving treatment approaches.
methodsFollowing PRISMA 2020 and JBI 2020 criteria, English-language case reports and series meeting predefined quality thresholds (≥ 75% or ≥ 70%) were retrieved from PubMed, Scopus, and Google Scholar. Two independent reviewers extracted demographic, imaging, and outcome data using standardized forms. Quantitative analysis was limited to descriptive summaries using SPSS v24, while qualitative synthesis consisted of a structured narrative and thematic organization of case-level clinical, imaging, and management data using NVivo 14.
resultsTwenty-five patients from 24 studies were included (median age 36 years, range 5 days–78 years; 56% male). Palpitations and dyspnea were the predominant symptoms; atrial arrhythmias occurred in 52%. Echocardiography (92%) served as the initial modality, while CT (84%) and MRI (28%) defined structure and thrombus. Histopathology indicated chronic fibrotic degeneration. Surgical or interventional management was performed in 79% and conservative therapy in 21%. Innovative procedures, thoracoscopic resection, RF ablation, and device-based WATCHMAN FLX occlusion, achieved excellent short-term outcomes. Overall survival was 88%, with fatalities mainly in neonatal or elderly patients.
conclusionsLAAA is a progressive dysplastic aneurysm presenting across ages. Multimodal imaging defines risk and guides individualized management. Emerging minimally invasive and device-based strategies complement conventional surgery, signaling a therapeutic shift. Ongoing data collection and imaging-pathology correlation are needed for standardized care of this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.